March Altus Capital Management as of Sept. 30, 2015
Portfolio Holdings for March Altus Capital Management
March Altus Capital Management holds 14 positions in its portfolio as reported in the September 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Edwards Lifesciences (EW) | 28.5 | $4.8M | 34k | 142.18 | |
| Gilead Sciences (GILD) | 9.9 | $1.7M | 17k | 98.18 | |
| ACADIA Pharmaceuticals (ACAD) | 9.5 | $1.6M | 49k | 33.08 | |
| Eli Lilly & Co. (LLY) | 8.3 | $1.4M | 17k | 83.71 | |
| Aratana Therapeutics | 5.5 | $935k | 111k | 8.46 | |
| Dex (DXCM) | 5.0 | $841k | 9.8k | 85.87 | |
| Medicines Company | 4.9 | $838k | 22k | 37.96 | |
| Regeneron Pharmaceuticals (REGN) | 4.8 | $817k | 1.8k | 465.26 | |
| Mallinckrodt Pub SHS | 4.8 | $816k | 13k | 63.90 | |
| Incyte Corporation (INCY) | 4.8 | $810k | 7.3k | 110.29 | |
| Medivation | 4.7 | $799k | 19k | 42.51 | |
| Neurocrine Biosciences (NBIX) | 4.1 | $692k | 17k | 39.80 | |
| Aerie Pharmaceuticals | 3.2 | $549k | 31k | 17.73 | |
| United Therapeutics Corporation (UTHR) | 1.9 | $328k | 2.5k | 131.20 |
